文章摘要
王晓翔,黄 蕾,温旭东,付国川,潘 涛.柴芩承气汤辅助治疗对急性胰腺炎患者Th17/Treg免疫失衡和外周血TLR4/NF-κB通路mRNA表达的影响[J].,2024,(4):739-742
柴芩承气汤辅助治疗对急性胰腺炎患者Th17/Treg免疫失衡和外周血TLR4/NF-κB通路mRNA表达的影响
Effect of Chaiqin Chengqi Decoction Adjuvant Therapy on Th17/Treg Immune Imbalance and Peripheral Blood TLR4/NF-κB Pathway mRNA Expression in Patients with Acute Pancreatitis
投稿时间:2023-06-03  修订日期:2023-06-26
DOI:10.13241/j.cnki.pmb.2024.04.027
中文关键词: 柴芩承气汤  急性胰腺炎  Th17/Treg免疫失衡  TLR4/NF-κB通路
英文关键词: Chaiqi chengqi decoction  Acute pancreatitis  Th17/Treg immune imbalance  TLR4/NF-κB pathway
基金项目:四川省科技计划项目(2021YJ0198)
作者单位E-mail
王晓翔 成都市第一人民医院(成都中医药大学附属中西医结合医院)消化内科 四川 成都 610041 wangxxcd23@163.com 
黄 蕾 成都市第一人民医院(成都中医药大学附属中西医结合医院)消化内科 四川 成都 610041  
温旭东 成都市第一人民医院(成都中医药大学附属中西医结合医院)消化内科 四川 成都 610041  
付国川 成都市第一人民医院(成都中医药大学附属中西医结合医院)消化内科 四川 成都 610041  
潘 涛 成都市第一人民医院(成都中医药大学附属中西医结合医院)消化内科 四川 成都 610041  
摘要点击次数: 344
全文下载次数: 300
中文摘要:
      摘要 目的:观察柴芩承气汤辅助治疗对急性胰腺炎(AP)患者辅助性T 细胞17(Th17)/调节性T细胞(Treg)免疫失衡和外周血Toll样受体4(TLR4)/核因子κB(NF-κB)通路mRNA表达的影响。方法:纳入2021年3月到2022年12月期间成都市第一人民医院收治的90例AP患者,按照随机数字表法分为对照组和实验组,各为45例。对照组患者接受常规西医治疗,实验组患者在对照组的基础上接受柴芩承气汤辅助治疗。对比两组疗效、中医证候评分、Th17/Treg免疫失衡相关指标、外周血TLR4/NF-κB通路mRNA表达。结果:实验组的临床总有效率高于对照组(P<0.05)。治疗1周后,两组腹痛剧烈、有痞满燥实坚征象、日晡潮热、恶心呕吐、小便短赤中医证候评分均下降,且实验组低于对照组(P<0.05)。治疗1周后,两组Th17细胞比例、Th17/Treg均下降,且实验组低于对照组(P<0.05),治疗1周后,两组Treg细胞比例升高,且实验组高于对照组(P<0.05)。治疗1周后,两组TLR4 mRNA、NF-κB mRNA均下降,且实验组低于对照组(P<0.05)。结论:柴芩承气汤辅助治疗AP患者,可提升治疗效果,降低中医证候积分,调节Th17/Treg免疫失衡和外周血TLR4/NF-κB通路mRNA表达。
英文摘要:
      ABSTRACT Objective: To observe the effect of chaiqin chengqi decoction adjuvant therapy on helper T cell 17 (Th17)/regulatory T cell (Treg) immune imbalance and peripheral blood Toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) pathway mRNA expression in patients with acute pancreatitis (AP). Methods: 90 AP patients who were admitted to Chengdu First People's Hospital from March 2021 to December 2022 were included. Patiens were divided into control group and experimental group according to the random number table method, 45 cases in each group. Patients in control group were treated with conventional western medicine, and patients in experimental group were treated with chaiqin chengqi decoction on the basis of control group. The efficacy, chinese medicine syndrome scores, Th17/Treg immune imbalance related indicators, and peripheral blood TLR4/NF-κB pathway mRNA expression were compared between two groups. Results: The total clinical effective rate in experimental group was higher than that in control group(P<0.05). 1 week after treatment, the chinese medicine syndrome scores syndromes of severe abdominal pain, fullness and dryness, hot flashes, nausea and vomiting, and short red urine in two groups decreased, and those in experimental group were lower than control group(P<0.05). 1 week after treatment, the proportion of Th17 cells and Th17/Treg in two groups decreased, and those in experimental group were lower than control group(P<0.05). 1 week after treatment, the proportion of Treg cells in two groups increased, and those in experimental group were higher than control group(P<0.05). 1 week after treatment, TLR4 mRNA and NF-κB mRNA in two groups decreased, and those in experimental group were lower than control group(P<0.05). Conclusion: Chaiqin chengqi decoction adjuvant treatment of AP patients can improve the therapeutic effect, reduce chinese medicine syndrome scores, regulate Th17/Treg immune imbalance and peripheral blood TLR4/NF-κB pathway mRNA expression.
查看全文   查看/发表评论  下载PDF阅读器
关闭